جست‌وجوی استاد و پژوهشگر

John Schimentiمشاهده پروفایل

استاد

• Genetics
• Meiosis
• Genome Maintenance
• +۵ مورد دیگر

John Schimenti is a James Law Professor of Genetics at the Department of Biomedical Sciences , Cornell University College of Veterinary Medicine . His research focuses on the genetics of reproduction , meiosis , and genome maintenance , particularly checkpoint mechanisms that prevent chromosomal aberrations and birth defects. He has developed CRISPR-based models for studying human infertility alleles. Education: BA from Rutgers University, PhD from University of Cincinnati Children's Hospital, Postdoctoral training at Princeton University Professional Experience: Assistant Professor at Case Western Reserve University (1987-1992), Staff Scientist at The Jackson Laboratory (1992-2004), Director of Cornell Center for Vertebrate Genomics (2004-2019) Research Interests span reproductive genetics, DNA replication stress responses, and mechanisms ensuring germ cell quality. His recent work explores epigenetic regulators in primordial germ cell development and organoid mutagenesis for ovarian cancer drivers. Publications cover meiotic recombination, infertility genetics, ovarian cancer modeling, and genome stability during development. Key areas include CHK2/CHK1 signaling , CDK2 functions , and RABL2A variants . Scientific Awards : March of Dimes Basil O'Connor Award, Searle Scholars Award, NSF Presidential Young Investigator, AAAS Fellow, SUNY Chancellor's Award Teaching includes BioMG Genomics 4000/6000 for 19+ years. Affiliations: Primary in Biomedical Sciences (Cornell CVM), Joint in Molecular Biology and Genetics.

• Mathematical Biology
• Computational Biology
• Stochastic Modeling
• +۱۲ مورد دیگر

Tomás Alarcón is an ICREA Research Professor at the Centre de Recerca Matemàtica (CRM) in Barcelona, Spain. He leads the Cancer Modeling Group and serves as Deputy Director of CRM since 2016. His work bridges mathematical biology, computational modeling, and biomedical applications. PhD in Theoretical Physics from the University of Barcelona (2000) Postdoctoral appointments at University of Oxford, University College London, and Imperial College London ICREA Research Professorship at CRM (2015–present) Research Interests: Dr. Alarcón specializes in multiscale modeling of tumor growth, stochastic processes in cell reprogramming, hybrid simulation methods , and microfluidic biophysics . His work integrates mathematical frameworks with biological complexity across spatial and temporal scales. Article Trends: Recent publications focus on chromatin folding , epigenetic landscapes , and angiogenesis mechanisms . Key themes include metabolic-cancer interactions , stochastic bistability , and computational immunology . Collaborations span institutions like the University of Oxford, UCL, and Heidelberg University. Scientific Leadership: As Deputy Director of CRM and member of the Catalan Mathematical Society's Scientific Committee, he has shaped mathematical biology research agendas. His advisory role extends to 15+ PhD/MSc students , now active across global institutions.

Jeremie Kalfonمشاهده پروفایل

پژوهشگر

• Computational Biology
• Bioinformatics
• Machine Learning in Genomics
• +۵ مورد دیگر

Jeremie Kalfon is a researcher at the Pasteur Institute in Paris, France, specializing in computational biology and gene regulatory network inference. His work focuses on leveraging machine learning and large-scale single-cell data analysis to unravel complex biological systems, particularly in cancer and immune diseases. Notably, he is a key contributor to the development of scPRINT , a transformer-based model for gene network prediction, batch correction, and denoising in genomics. Primary Affiliation : Pasteur Institute (Institut Pasteur) Research Themes : Computational biology, bioinformatics, leukemia genomics, single-cell RNA-seq modeling Research Trends : Kalfon’s publications demonstrate expertise in: Designing AI-driven tools for gene network inference Uncovering transcriptional plasticity in leukemia Mapping synthetic lethal interactions in cancers Decoding codon usage patterns and metabolic vulnerabilities Grant Support : ANR-16-CONV-0005 (French National Research Agency) European Research Council H2020 grant #101115618 Collaborative Networks : He collaborates with interdisciplinary teams at Pasteur Institute and contributes to educational workshops on AI in life sciences, reflecting his commitment to training the next generation of computational biologists.

Philippe J. Sansonettiمشاهده پروفایل

استاد

• Microbiology
• Infectious Diseases
• Vaccinology
• +۷ مورد دیگر

Philippe J. Sansonetti is a Professor at the Pasteur Institute and Collège de France in Paris, serving as Director of the Inserm Unit 786 and the Institut Pasteur laboratory Molecular Microbial Pathogenesis . His work bridges microbiology, immunology, and public health, with a focus on bacterial pathogenesis and microbiome interactions. Key Affiliations : Pasteur Institute, Paris Collège de France, Chair of Microbiology and Infectious Diseases Inserm Unit 786 Research Interests center on Shigella pathogenesis, mucosal immunity, and microbiota-host interactions in diseases like endometriosis and childhood malnutrition. He explores how microbial communities influence conditions ranging from diarrheal disease to colorectal cancer, integrating structural biology and systems approaches. Recent Publications highlight advancements in synthetic glycan-based vaccines, mechanisms of oral microbiota in stunting, and immune dynamics in endometriosis. His work spans PNAS , Nutrients , and Nature Microbiology , emphasizing translational impact and global health applications. Advising includes mentoring postdoctoral fellows like Julia Hehner and Özmen Çobanoglu , alongside master's students such as Paul Courrieu . His laboratory has led projects like AFRIBIOTA (investigating microbiota in sub-Saharan Africa) and MITICA (environmental enteropathy mechanisms).

• Computational Biology
• Bioinformatics
• Multi-Omics Integration
• +۶ مورد دیگر

Ana Rita Grosso is an Assistant Professor at the Department of Life Sciences , NOVA School of Science and Technology (FCT-NOVA) , NOVA University Lisbon , and heads the Computational Multi-Omics Group . Since 2018 she has built an independent research program focused on leveraging multi-omics to decode cancer and other pathologies. Education PhD in Biomedical Sciences, Faculty of Medicine, University of Lisbon (iMM/FMUL, 2010) MSc in Bioinformatics, Faculty of Sciences, University of Lisbon (FCUL-IGC, 2006) Licenciatura (BSc) in Biology, Faculty of Sciences, University of Lisbon (FCUL, 2002) Research Interests Grosso’s work sits at the intersection of computational biology , bioinformatics , and biomedicine . She integrates large-scale genomics, transcriptomics, and epigenomics datasets to uncover molecular events underlying tumor evolution, metastasis, and tissue-specific splicing regulation, aiming to translate findings into biomarkers and therapeutic targets. Scientific Awards & Grants 3 × Pfizer Awards for Basic Research 10 competitive project grants (4 as PI/Co-PI, 6 as team member) 4 salary/stipend grants (PhD, Post-Doc, and 2 research contracts) EMBO Workshop Grant Advising & Training She has supervised 4 PostDocs , 3 PhD students , 3 MSc fellows , 10 MSc students , 7 BSc students , and numerous short-term trainees, while teaching Genomics and Computational Biology courses at FCT-NOVA. Laboratory & Teams She founded and leads the Computational Multi-Omics Lab at FCT-NOVA, an interdisciplinary team applying systems-biology approaches to cancer and biomedical questions.

• Chromatin Structure and Function
• Epigenetics
• DNA Repair
• +۳ مورد دیگر

Katherine West is a Senior Lecturer in Molecular Biosciences at the University of Glasgow. Her research focuses on chromatin-binding proteins, particularly the HMGN family, and their roles in DNA repair, gene expression, and stem cell biology. She has contributed to advancements in CRISPR-Cas9 technology, epigenetic regulation of pluripotency, and cancer-related education methodologies. Key Research Themes: Epigenetic mechanisms in stem cell differentiation HMGN protein function in chromatin dynamics CRISPR-Cas9 optimization for transgene integration Interdisciplinary medical education innovations Grant History: Research funded by Tenovus Scotland, BBSRC, AICR, and European Commission for projects spanning DNA repair, HMGN protein engineering, and cancer therapy sensitization.

• T Cell Biology
• Immunotherapy
• CRISPR Screening
• +۳ مورد دیگر

Sumana Sharma is a Wellcome Career Development Fellow and Group Leader at the MRC Weatherall Institute of Molecular Medicine (University of Oxford). Her research focuses on T-cell signaling and next-generation immunotherapy design , particularly through inhibitory receptor signaling manipulation . PhD in genetic screening (Wellcome Sanger Institute, University of Cambridge) Postdoc in computational analysis (EMBL-EBI, Cambridge) Former Sir Henry Wellcome Postdoctoral Fellow (MRC-TIDU, Oxford) Her work integrates CRISPR-based functional genomics , omics technologies , and primary T-cell editing to uncover regulatory mechanisms in immune suppression. Key contributions include developing CEN-tools for cancer gene analysis and creating high-throughput assays for T-cell signaling. Recent publications span 2025-2015 , emphasizing T-cell antigen detection , inhibitory signaling , and transcriptional reprogramming . Her research trends combine structural immunology , computational genomics , and therapeutic engineering . Wellcome Career Development Award Sir Henry Wellcome Postdoctoral Fellowship Her lab uses multidisciplinary approaches to study immune regulation in cancer and chronic infections , with potential applications in autoimmune disease and tumor immunotherapy .

• Haematology
• Oncology
• Epigenetics
• +۳ مورد دیگر

Richard Salisbury is a CRUK Clinical Research Training Fellow at the University of Oxford, affiliated with Hertford College. His research focuses on molecular mechanisms in haematological malignancies, particularly Chronic Myelomonocytic Leukaemia (CMML). His core research interests include: Haematology Oncology Epigenetics Cancer Research Stem Cell Biology Molecular Biology Salisbury investigates TET2 loss-of-function mutations (present in 60% of CMML patients) using multiomic single-cell profiling. His work demonstrates that TET2-mutant haematopoietic stem and progenitor cells (HSPCs) are epigenetically reprogrammed to hijack emergency myelopoiesis pathways, causing hypersensitivity to bone marrow niche cytokines like M-CSF. Current research aims to identify druggable pathways for novel anti-cancer therapies in CMML. No scientific awards were mentioned in the source material. No information regarding student advising or research grants was provided in the available text.

Henry H. Roehlمشاهده پروفایل

مدرس ارشد

• Regenerative Biology
• Developmental Biology
• Cell Biology
• +۳ مورد دیگر

Dr. Henry H. Roehl is a Senior Lecturer at the School of Biosciences , University of Sheffield. His career spans over 25 years in academic roles, including Lecturer at University of Sheffield (2002-present) and Postdoctoral Fellow at Max-Planck-Institut, Tuebingen (1997-2002). PhD in Genetics (University of Wisconsin-Madison, 1994-1997) Masters in Genetics (University of Wisconsin-Madison, 1990-1994) B.S. in Biology (Antioch College, 1983-1988) His research focuses on regenerative biology using zebrafish models to understand: (1) cellular recruitment during regeneration, and (2) signaling pathways initiating regenerative processes. Current studies explore molecular pathways guiding tissue regeneration, particularly in skeletal and craniofacial development. Recent publications highlight his work on Tetraspanin Cd9b's role in fertility , Wnt/FGF signaling synergy , and Hedgehog-dependent osteoblast differentiation . Over 20 years of publications demonstrate consistent contributions to developmental biology and regenerative medicine. Dr. Roehl supervises PhD students Yuqi An and Yuchang Liu , and has secured grants from BBSRC and Leverhulme Trust. He also serves as Founding Secretary of the International Society for Regenerative Biology since 2020.

Nicholas Bradyمشاهده پروفایل

استادیار

• Cancer Biology
• Epigenetics
• Transcriptional Regulation
• +۵ مورد دیگر

Nicholas Brady is an Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine's Graduate School of Medical Sciences, where he leads the Brady Lab. The lab focuses on neuroendocrine prostate cancer (NEPC) and lineage plasticity in castration-resistant prostate cancer (CRPC), employing in vitro and in vivo models for mechanistic studies. Education: Bachelor's in Physics from Boston University Ph.D. from the University of Minnesota under Dr. Kathryn Schwertfeger, studying mammary gland development and JAK/STAT signaling in breast cancer Postdoctoral training at Weill Cornell Medicine with Dr. David Rickman on N-Myc in NEPC Brady Lab's research investigates chromatin state changes driving NEPC progression and identifies transcriptional regulators cooperating with epigenetic alterations. Current projects include Regulation of chromatin states during progression to NEPC , Identifying novel transcriptional drivers , and Understanding the tumor microenvironment . His work utilizes human prostate cancer cell lines, patient-derived organoids, and transgenic mice with single-cell next-generation sequencing. Scientific Awards: MTOR Training Program Fellow (2018-2019) American Cancer Society Postdoctoral Fellowship (2021-2022) JumpStart Research Career Development Award (2021-2024) NCI Transition Career Development Award (K22) (2024) Brady's research has been supported by grants including the WCM JumpStart Program, WCM SPORE in Prostate Cancer Career Enhancement Program, and targeted tumor heterogeneity research funding. His publications reflect expertise in chromatin biology, lineage plasticity, and prostate cancer genomics.

Xin Jiangمشاهده پروفایل

پژوهشگر ارشد

• Structural Biology
• Biochemistry
• Membrane Protein Mechanisms
• +۳ مورد دیگر

Dr. Xin Jiang is a Senior Research Fellow at the School of Biotech & Biomolecular Science, University of New South Wales (UNSW), specializing in structural biology and biochemistry. He investigates membrane protein mechanisms and their therapeutic applications, particularly focusing on malaria and cancer metabolism. PhD in 2017 from Tsinghua University under Prof. Yigong Shi Postdoctoral training at Princeton University (2018) with Prof. Nieng Yan Joined UNSW in 2019 Research interests include: Decoding Plasmodium membrane proteins for antimalarial drug development Exploring lipid/cholesterol biogenesis mechanisms in collaboration with BABS senior lipid researchers Publications highlight expertise in glucose/lactate transporters, the Warburg effect, and transporter inhibition strategies. His work spans structural analysis of the Plasmodium falciparum hexose transporter, monocarboxylate transporters, and dual inhibitors targeting malaria and cancer metabolism.

• Neurodegenerative Diseases
• Stem Cell Modeling
• Alzheimer's Disease Research
• +۲ مورد دیگر

Dr. Simon Maksour serves as the Race Against Dementia – Dementia Australia Research Foundation Research Fellow (2025-2030) within the School of Medical Sciences at the University of Sydney's Faculty of Medicine and Health. His research bridges molecular neuroscience and therapeutic development for neurodegenerative disorders. Dr. Maksour's research focuses on modeling neurodegenerative diseases using induced pluripotent stem cells (iPSCs) to generate neural cells and organoids. His work spans Alzheimer's disease , Motor Neuron Disease , Friedreich's ataxia , Vanishing White Matter disease , Huntington's disease , and Parkinson's disease . Current projects target microglia-specific therapies for Alzheimer's disease, including gene therapy validation in advanced stem cell models and microglial cell replacement strategies. His publication record demonstrates consistent output in high-impact journals, with recent first-author papers in BMC Biology (2025), Frontiers in Cellular Neuroscience (2024), and Antioxidants & Redox Signaling (2024). Research themes include: Neurosciences and Mental Health Healthy Ageing Cellular/Molecular mechanisms of neurodegeneration Therapeutic interventions for dementia Dr. Maksour received the Australasian Society for Stem Cell Research (ASSCR) Rising Star Award for his contributions to stem cell modeling of neurodegenerative conditions. His work has been featured in media outlets including 2GB Sydney and UOW communications. As an active supervisor, he offers PhD and honours projects in microglia-targeted Alzheimer's therapies, microglial replacement strategies, and neuroprotective compound screening using brain organoids. His Race Against Dementia Fellowship provides dedicated funding through 2030 for developing novel therapeutic approaches.

Zhongjian Chengمشاهده پروفایل

استادیار

• Cardiovascular Medicine
• Diabetes and Metabolic Disorders
• Endothelial Dysfunction
• +۴ مورد دیگر

Zhongjian Cheng, PhD, is an Assistant Professor in the Department of Cardiovascular Sciences at Temple University's Lewis Katz School of Medicine. His research focuses on diabetes-mediated cardiovascular complications, particularly the mechanisms of vascular injury, endothelial dysfunction, and myocardial repair. He investigates extracellular vesicles/exosomes from diabetic cells and their modification via genetic, epigenetic, and metabolite approaches to enhance regenerative properties. Education: PhD from University of Helsinki; Postdoctoral fellowship at University of Calgary Affiliation: Member of the Aging + Cardiovascular Discovery Center Dr. Cheng's work spans diabetic cardiovascular complications , extracellular vesicle biology , epigenetic modifications , and non-coding RNA (circular RNA, miRNA). His studies use animal models to explore vascular relaxation impairments , myocardial infarction , and heart failure mechanisms. His recent publications highlight exosome-based therapeutics for heart failure, epigenetic sex differences in cardiac repair, and circRNA/miRNA roles in macrophage and endothelial cell function. Key awards include multiple American Heart Association grants .

• Oncology
• Molecular Biology of Cancer
• Medical Genetics
• +۷ مورد دیگر

Prof. Semra Demokan is a faculty member at Istanbul University, Institute of Oncology, Department of Basic Oncology. She holds a Professor rank and has been active since 2017. Her academic journey includes postdoctoral research at Johns Hopkins University, School of Medicine, and degrees from Bogazici University and Istanbul University. Doctorate: Oncological Biology and Immunology, Istanbul University Postgraduate: Oncological Biology and Immunology, Istanbul University Undergraduate: Molecular Biology and Genetics, Bogazici University Research interests span Oncology , Molecular Biology of Cancer , Epigenetics , Genetics , and Clinical Medicine . She focuses on DNA methylation , gene expression profiling , and epigenetic biomarkers in head and neck/oral cancers. Her 15 most recent publications (2023-2010) cover epigenetic mechanisms in cancer, gene expression analysis , DNA repair pathways , and biomarker validation . Key subtopics include head and neck squamous cell carcinoma , oral cancer methylomics , microRNA interactions , and tumor suppressor gene regulation . Advisory roles include supervising 17 postgraduate theses (2024-2017) on topics like SETD2 expression in parotid tumors , TXNIP gene in oral cancer , and mitochondrial biogenesis in oral lesions . She participates in institutional management as Head of Department (2013-present) and coordinates Erasmus programs.

Gregory Verdineمشاهده پروفایل

استاد

• Chemical Biology
• Epigenetics
• DNA Repair
• +۵ مورد دیگر

Gregory Verdine is the Erving Professor of Chemistry at Harvard University, with primary appointments in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology. He is a pioneering figure in chemical biology, DNA repair mechanisms, and therapeutic modality development, particularly known for inventing stapled peptides that target previously "undruggable" proteins. Verdine also serves as Chairman of the Board of Directors at WaVe Life Sciences and President/CEO of FogPharma, while maintaining advisory roles at institutions like Memorial Sloan-Kettering Research Institute and National Cancer Institute. Harvard University (Stem Cell and Regenerative Biology, Chemistry and Chemical Biology) Founder/Co-Founder of 8 biotech companies (Enanta, Gloucester, Tokai, WaVe, Eleven Biotherapeutics, Warp Drive Bio, Aileron, FogPharma) Non-Profit Leadership: Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy Research focuses on chemical biology and genomic stability , with key discoveries in: Molecular mechanisms of epigenetic DNA methylation Genotoxic DNA damage surveillance pathways Design of stapled peptides for protein-protein interaction modulation Applications in oncology (β-catenin, Ras, RAB25 targeting) Advancing nucleotide excision repair systems Antisense oligonucleotide stereochemical optimization His 15 most recent publications (2013-2024) reveal trends in: Covalent enzyme inhibitors Genomic modality discovery Ubiquitin ligase reprogramming Protein structure remodelling Allele-selective genetic therapies DNA lesion recognition mechanisms Awards include the 2024 AACR Award for Excellence in Chemistry in Cancer Research and Nobel Laureate Signature Award . He has translated academic research into clinical applications through multiple FDA-approved drugs (romidepsin, paritaprevir) and currently leads FogPharma's Cell-Penetrating Miniprotein platform. Academic collaborators span Harvard, MIT, and major biomedical research institutions.